UNIKUM Therapeutics ApS: Financial statements 2020
CVR: 41192925
Source: annual report 2020, Danish Business Authority
17/02/2020 – 31/12/2020
UNIKUM Therapeutics ApS (CVR 41192925) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,099,415 and a net result of DKK -2,132,103. Equity in the 2020 report amounted to DKK -2,092,103. The company had 2 employees in the financial year.
- Gross Profit
- DKK -1,099,415
- Profit/Loss
- DKK -2,132,103
- Equity
- DKK -2,092,103
- Total Assets
- DKK 2,262,998
- Employees
- 2
Official annual report
How creditworthy is UNIKUM Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of February 17, 2020, Martin Roelsgaard Jakobsen has joined the board of directors of UNIKUM Therapeutics ApS.
As of February 17, 2020, Ulrik Bjerl Nielsen has joined the board of directors of UNIKUM Therapeutics ApS.
As of February 17, 2020, Søren Sylvester Skjærbæk is registered as director of UNIKUM Therapeutics ApS.
UNIKUM Therapeutics ApS was founded on February 17, 2020.
About UNIKUM Therapeutics ApS
UNIKUM Therapeutics ApS is a Danish company of the type Anpartsselskab based in Risskov, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Roelsgaard Jakobsen. The board consists of Ulrik Bjerl Nielsen (chair), Martin Roelsgaard Jakobsen and Stefan Wildt. The company's owners include MEDIC ADVICE ApS, MR Jakobsen Holding ApS and BII Holdings A/S. The company has 2 employees (2025). In 2025, the company reported a gross profit of DKK -247,887 and a net result of DKK -859,076 compared with DKK -13,797,011 the year before. Equity in the 2025 report amounted to DKK -5,680,033.
